| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,436,450 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-05-17 |
4 |
AS |
$215.31 |
$17,093 |
D/D |
(79) |
33,589 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-11-15 |
4 |
AS |
$186.80 |
$6,365 |
D/D |
(34) |
33,589 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-21 |
4 |
AS |
$421.77 |
$1,266,154 |
D/D |
(3,002) |
34,022 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-18 |
4 |
AS |
$241.80 |
$762,201 |
D/D |
(3,128) |
34,346 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
OE |
$155.57 |
$570,786 |
D/D |
3,669 |
35,222 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-25 |
4 |
OE |
$187.53 |
$733,242 |
D/D |
3,910 |
35,463 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-04 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
35,679 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-03 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
35,679 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-25 |
4 |
AS |
$229.41 |
$1,748,990 |
D/D |
(7,572) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-07-19 |
4 |
AS |
$286.72 |
$5,156,730 |
D/D |
(17,865) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
AS |
$290.32 |
$381,469 |
D/D |
(1,304) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-11-07 |
4 |
AS |
$299.72 |
$394,859 |
D/D |
(1,303) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-11-15 |
4 |
AS |
$308.61 |
$10,493 |
D/D |
(34) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-08-19 |
4 |
OE |
$86.52 |
$1,290,681 |
D/D |
12,501 |
36,212 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$1,147,806 |
D/D |
(3,970) |
36,276 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-24 |
4 |
D |
$217.57 |
$525,649 |
D/D |
(2,416) |
36,617 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-20 |
4 |
AS |
$420.79 |
$1,684,002 |
D/D |
(4,002) |
37,024 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-11 |
4 |
AS |
$179.46 |
$5,939,188 |
D/D |
(32,956) |
37,177 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-11-07 |
4 |
OE |
$187.53 |
$244,352 |
D/D |
1,303 |
37,380 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
37,381 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$602,784 |
D/D |
(2,496) |
37,474 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-18 |
4 |
AS |
$210.11 |
$1,657,590 |
D/D |
(7,825) |
39,033 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-06-29 |
4 |
AS |
$161.57 |
$7,313,596 |
D/D |
(44,331) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-07-16 |
4 |
AS |
$182.00 |
$4,254,250 |
D/D |
(23,375) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-02 |
4 |
AS |
$174.59 |
$313,564 |
D/D |
(1,796) |
39,113 |
0 |
- |
|
157 Records found
|
|
Page 3 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
